SCP2, sterol carrier protein 2, 6342

N. diseases: 50; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.030 Biomarker disease BEFREE Studies in vitro have suggested that both sterol carrier protein-2/sterol carrier protein-x (<i>Scp-2/Scp-x</i>) and liver fatty acid binding protein [<i>Fabp1</i> (L-FABP)] gene products facilitate hepatic uptake and metabolism of lipotoxic dietary phytol. 28411199 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.030 Biomarker disease BEFREE In vitro studies suggest that liver fatty acid binding protein (L-FABP) and sterol carrier protein-2/sterol carrier protein-x (SCP2/SCPx) gene products facilitate uptake and metabolism and detoxification of dietary-derived phytol in mammals. 27940000 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.030 AlteredExpression disease BEFREE Primarily in female mice, hepatic cholesterol accumulation induced by SCP-2 overexpression was associated with increased levels of LDL-receptor, HDL-receptor scavenger receptor-B1 (SR-B1) (as well as PDZK1 and/or membrane-associated protein 17 kDa), SCP-2, liver fatty acid binding protein (L-FABP), and 3alpha-hydroxysteroid dehydrogenase, without alteration of other proteins involved in cholesterol uptake (caveolin), esterification (ACAT2), efflux (ATP binding cassette A-1 receptor, ABCG5/8, and apolipoprotein A1), or oxidation/transport of bile salts (cholesterol 7alpha-hydroxylase, sterol 27alpha-hydroxylase, Na(+)/taurocholate cotransporter, Oatp1a1, and Oatp1a4). 19289417 2009